Molnupiravir

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H372：長期にわたる、または反復暴露により臓器の障 害

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P314：気分が悪い時は、医師の診断/手当てを受けること。

  P501：内容物/容器を．．．に廃棄すること。

Molnupiravir 価格

Molnupiravir 化学特性,用途語,生産方法

• 説明

  EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.

• 来歴

  Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-prot biotechnology company wholly owned by Emory University, and with partial funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck.

• 定義

  Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It derives from a N(4)-hydroxycytidine.
  www.ebi.ac.uk

• 生物活性

  EIDD-2801 is an orally active, 5′-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively).

• 規制状況(Regulatory Status)

  Molnupiravir (as EIDD-2801) was developed at Drug Innovation Ventures at Emory (DRIVE), a not-forprofit biotechnology company owned by Emory University, Atlanta. It was then licensed by Ridgeback Biotherapeutics, and is now developed further in cooperation with Merck & Co. (in Europe: Merck Sharp & Dohme/ MSD).
  Molnupiravir is not approved by the European Medicines Agency (EMA) or the American Food and Drug Administration (FDA).

• 参考文献

  [1] Toots M, Yoon J-J, Cox RM et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine 2019;11(515). Epub 23 Oct 2019.
  [2] Toots M, Yoon J-J, Hart M et al. . Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model. Transl Res 2020. Epub 2019 Dec 25.
  [3] Halford B. An emerging antiviral takes aim at COVID-19. American Chemical Society; 2020 [14.12.2020]; Available from: https://cen.acs.org/pharmaceuticals/drug-development/emergingantiviral-takes-aim-COVID-19/98/web/2020/05.
  [4] Ridgeback Biotherapeutics. OVERVIEW OF EIDD-2801 (MK-4482). [Presentation]. provided via email 2020.

Molnupiravir 生産企業

Global(301)Suppliers

Molnupiravir スペクトルデータ(¹HNMR)

2349386-89-4, Molnupiravir キーワード